Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Background Recommendations against prostate-specific antigen (PSA) testing in 2012 have
increased advanced-stage diagnosis and prostate cancer–specific mortality rates. Objective …

In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic
prostate cancer and died of the disease; after the introduction of the serum PSA test …

Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …

Background Whether multiparametric MRI improves the detection of clinically significant
prostate cancer and avoids the need for systematic biopsy in biopsy-naive patients remains …

Context It remains unclear whether patients with a suspicion of prostate cancer (PCa) and
negative multiparametric magnetic resonance imaging (mpMRI) can safely obviate prostate …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Prostate cancer is a common malignancy seen worldwide. The incidence has risen in recent
decades, mainly fuelled by more widespread use of prostate-specific antigen (PSA) testing …

Context Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid
since the introduction of new technologies such as risk calculators (RCs) and magnetic …

Abstract Background The Rotterdam European Randomized Study of Screening for Prostate
Cancer risk calculators (ERSPC-RCs) help to avoid unnecessary transrectal ultrasound …